Annual report pursuant to Section 13 and 15(d)

Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)

v3.23.1
Schedule of Deferred Tax Assets and Related Valuation Allowances (Details) - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Income Tax Disclosure [Abstract]    
Reserves and other $ 745,000 $ 179,000
Net operating loss carry-forwards 26,176,000 23,526,000
Capitalized research and development 2,177,000
Research and development tax credit 610,000 610,000
Share-based compensation 4,542,000 4,021,000
Valuation Allowance (34,250,000) (28,336,000)
Net deferred tax asset